亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Phase I/II study of DZD6008, a 4 th -generation EGFR TKI with full BBB penetration, in EGFR-mutant NSCLC.

医学 突变体 肿瘤科 吉非替尼 内科学 癌症研究 表皮生长因子受体 基因 受体 遗传学 生物
作者
Mengzhao Wang,Ying Hu,Yan Xu,Weiheng Hu,Hua Zheng,Mengzhu Zhang,Xiaomei Pan,Lina Zheng,Jian Fang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 8616-8616
标识
DOI:10.1200/jco.2025.43.16_suppl.8616
摘要

8616 Background: NSCLC patients whose disease progressed after 3 rd generation EGFR TKI treatment often have CNS metastasis and acquired EGFR resistance mutations, such as C797S mutation. DZD6008 is a 4 th generation EGFR TKI, designed to target EGFR sensitizing mutations (L858R/del19), resistant double (T790M and L858R/del19) and triple mutations (C797X, T790M and L858R/del19). Preclinical data shows that DZD6008 has high selectivity against wildtype EGFR and other kinases and is fully blood-brain-barrier (BBB) penetrant. Here we report results from the ongoing phase 1/2 studies in advanced EGFR mutation positive (EGFRm) NSCLC. Methods: TIAN-SHAN2 (CTR20241790) is a multi-center, first-in-human phase 1/2 study with expansion designed to evaluate the safety, tolerability, and anti-tumor activity of DZD6008 in EGFRm NSCLC patients who failed prior EGFR TKI treatment. DZD6008’s BBB penetration capability was evaluated by measuring the ratio of free drug concentrations in CSF and blood, as well as tumor response of brain lesions. Results: Preclinically, DZD6008 showed equal potencies against multiple variants of single, double or triple EGFR mutations, with >50-fold selectivity over wild-type EGFR. In osimertinib-resistant CDX and PDX models carrying EGFR triple mutations, DZD6008 induced profound tumor shrinkage in a dose-dependent manner. As of December 24, 2024, 12 patients with EGFRm NSCLC had been enrolled into dose escalation cohorts of TIAN-SHAN2 study, and treated with DZD6008 at 20 mg to 90 mg once daily (QD). The median age was 61 years, 67% were female, and 50% had an ECOG PS of 1. All patients had adenocarcinoma and carried various types of single, double or triple EGFR mutations. The median lines of prior therapies was 5 (range 2 - 8). All patients had been treated with EGFR TKIs and chemotherapy, and 11 had received prior third-generation EGFR TKI treatment. DZD6008 was well tolerated across the doses investigated, and no dose limiting toxicities were reported. The maximum tolerated dose was not reached. DZD6008 exhibited dose-proportional and linear pharmacokinetic characteristics, with excellent blood-brain-barrier penetration (CSF to free plasma ratio >1) in patients with baseline brain metastasis. Ten out of 12 patients (83.3%) showed target lesion tumor shrinkage following DZD6008 treatment. Partial response was observed at ≥ 20 mg in patients with various EGFR mutations. Anti-tumor activity was observed in patients with brain metastasis. The longest duration on treatment was >6 months (treatment ongoing). Conclusions: DZD6008 is a novel, highly selective, full-BBB penetrant EGFR TKI with broad-spectrum of activity against different EGFR mutations. In heavily pre-treated EGFRm NSCLC patients, DZD6008 monotherapy was well-tolerated and showed encouraging anti-tumor activity. TIAN-SHAN2 study is ongoing and updated data will be presented at the meeting. Clinical trial information: CTR20241790 .
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
岁岁平岁岁安完成签到,获得积分20
3秒前
可爱的函函的应助被沃沃爹采纳,获得10
3秒前
七七完成签到,获得积分10
4秒前
jcz完成签到,获得积分10
7秒前
7秒前
12秒前
why完成签到 ,获得积分10
13秒前
淡然的半烟完成签到,获得积分10
15秒前
沃沃爹发布了新的文献求助10
17秒前
23秒前
痴情的皮皮虾完成签到,获得积分10
24秒前
郭浩瑞完成签到,获得积分20
25秒前
科研通AI6.2的应助被hyman采纳,获得10
26秒前
37秒前
yangm9发布了新的文献求助10
40秒前
乐迪发布了新的文献求助10
43秒前
科研通AI6.2的应助被纪十三采纳,获得10
44秒前
45秒前
112233完成签到 ,获得积分10
45秒前
47秒前
沃沃爹完成签到,获得积分10
48秒前
50秒前
Yuan发布了新的文献求助10
50秒前
欢喜的小海豚完成签到,获得积分10
51秒前
53秒前
55秒前
庾傀斗发布了新的文献求助10
58秒前
庾傀斗发布了新的文献求助10
58秒前
庾傀斗发布了新的文献求助10
59秒前
Rebirth发布了新的文献求助10
1分钟前
呼延香之完成签到,获得积分10
1分钟前
1分钟前
直率的宛丝完成签到,获得积分10
1分钟前
1分钟前
null的应助被科研通管家采纳,获得10
1分钟前
1分钟前
科研通AI65的应助被科研通管家采纳,获得10
1分钟前
Lawer发布了新的文献求助10
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184980
求助须知:如何正确求助?哪些是违规求助? 9573917
关于积分的说明 21833751
捐赠科研通 7782440
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161